Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kunte

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Clinical Nuclear Medicine|October 2, 2024
Lenticulostriatal Ischemia Shows Relevant SSTR Expression on PET/CT Imaging Using the Novel SSTR-Targeting Peptide 18 F-SiTATESophie C Kunte, Lena M Unterrainer, Wolfgang G Kunz, et al.
Cancers|May 14, 2025
Comparison of the Hematotoxicity of PRRT with Lutathera<sup>®</sup> and Locally Manufactured <sup>177</sup>Lu-HA-DOTATATE in Patients with Neuroendocrine Tumors and the Impact of Different Application IntervalsMarkus Hofmann, Sophie C Kunte, Marcus Unterrainer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 23, 2022
Health-related quality of life trajectories in melanoma patients after electrochemotherapy: real-world insights from the InspECT registerL G Campana, P Quaglino, F de Terlizzi, et al.
Neuro-Oncology|November 19, 2024
Measurable disease as baseline criterion for response assessment in glioblastoma: A comparison of PET -based (PET RANO 1.0) and MRI-based (RANO) assessmentsKatharina J Müller, Robert Forbrig, Jonas Reis, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 11, 2025
Feasibility of a single-day protocol for SPECT and PET assessment of dopamine transporter availability, cardiac innervation and metabolic patterns in patients with movement disordersMaximilian Scheifele, Johannes Gnörich, Elisabeth Schröder, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 18, 2024
[<sup>68 </sup>Ga]Ga-FAPI-46 PET/CT for locoregional lymph node staging in urothelial carcinoma of the bladder prior to cystectomy: initial experiences from a pilot analysisLena M Unterrainer, Lennert Eismann, Simon Lindner, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 15, 2024
PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [<sup>18</sup>F]SiTATE - first clinical experiencesSophie C Kunte, Vera Wenter, Johannes Toms, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 24, 2025
<sup>68</sup>Ga-FAPI and <sup>18</sup>F-FAPI PET/CT for detection of nodal metastases prior radical cystectomy in high-risk urothelial carcinoma patientsLena M Unterrainer, Hans P Schmid, Sophie C Kunte, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 29, 2023
Correction to: Next‑generation PET/CT imaging in meningioma-first clinical experiences using the novel SSTR‑targeting peptide [<sup>18</sup>F]SiTATEMarcus Unterrainer, Sophie C Kunte, Lena M Unterrainer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 26, 2023
Next-generation PET/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [<sup>18</sup>F]SiTATEMarcus Unterrainer, Sophie C Kunte, Lena M Unterrainer, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Clinical Nuclear Medicine|October 2, 2024
Lenticulostriatal Ischemia Shows Relevant SSTR Expression on PET/CT Imaging Using the Novel SSTR-Targeting Peptide 18 F-SiTATESophie C Kunte, Lena M Unterrainer, Wolfgang G Kunz, et al.
Cancers|May 14, 2025
Comparison of the Hematotoxicity of PRRT with Lutathera<sup>®</sup> and Locally Manufactured <sup>177</sup>Lu-HA-DOTATATE in Patients with Neuroendocrine Tumors and the Impact of Different Application IntervalsMarkus Hofmann, Sophie C Kunte, Marcus Unterrainer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 23, 2022
Health-related quality of life trajectories in melanoma patients after electrochemotherapy: real-world insights from the InspECT registerL G Campana, P Quaglino, F de Terlizzi, et al.
Neuro-Oncology|November 19, 2024
Measurable disease as baseline criterion for response assessment in glioblastoma: A comparison of PET -based (PET RANO 1.0) and MRI-based (RANO) assessmentsKatharina J Müller, Robert Forbrig, Jonas Reis, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 11, 2025
Feasibility of a single-day protocol for SPECT and PET assessment of dopamine transporter availability, cardiac innervation and metabolic patterns in patients with movement disordersMaximilian Scheifele, Johannes Gnörich, Elisabeth Schröder, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 18, 2024
[<sup>68 </sup>Ga]Ga-FAPI-46 PET/CT for locoregional lymph node staging in urothelial carcinoma of the bladder prior to cystectomy: initial experiences from a pilot analysisLena M Unterrainer, Lennert Eismann, Simon Lindner, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 15, 2024
PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [<sup>18</sup>F]SiTATE - first clinical experiencesSophie C Kunte, Vera Wenter, Johannes Toms, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 24, 2025
<sup>68</sup>Ga-FAPI and <sup>18</sup>F-FAPI PET/CT for detection of nodal metastases prior radical cystectomy in high-risk urothelial carcinoma patientsLena M Unterrainer, Hans P Schmid, Sophie C Kunte, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 29, 2023
Correction to: Next‑generation PET/CT imaging in meningioma-first clinical experiences using the novel SSTR‑targeting peptide [<sup>18</sup>F]SiTATEMarcus Unterrainer, Sophie C Kunte, Lena M Unterrainer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 26, 2023
Next-generation PET/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [<sup>18</sup>F]SiTATEMarcus Unterrainer, Sophie C Kunte, Lena M Unterrainer, et al.
Pageof 6